RTOG0617_2B | R Documentation |
Kaplan-Meier digitized data from RTOG0617, figure 2B (PMID 25601342). A reported sample size of 166 for a primary endpoint of OS in lung cancer.
RTOG0617_2B
A data frame of 465 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (cetuximab, no_cetuximab) | |
Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16: 187–99.
summary(RTOG0617_2B)
kmplot(RTOG0617_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.